Jump to main content
Jump to site search

Issue 1, 2016
Previous Article Next Article

Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy

Author affiliations

Abstract

Many small-molecule anti-cancer drugs have short blood half-lives and toxicity issues due to non-specificity. Nanotechnology has shown great promise in addressing these issues. Here, we report the development of anti-cancer drug gemcitabine-conjugated iron oxide nanoparticles for glioblastoma therapy. A glioblastoma targeting peptide, chlorotoxin, was attached after drug conjugation. The nanoparticles have a small size (∼32 nm) and uniform size distribution (PDI ≈ 0.1), and are stable in biological medium. The nanoparticles effectively enter cancer cells without losing potency compared to the free drug. Significantly, the nanoparticles showed a prolonged blood half-life and the ability to cross the blood–brain barrier in wild type mice.

Graphical abstract: Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 Oct 2015, accepted on 24 Nov 2015 and first published on 24 Nov 2015


Article type: Communication
DOI: 10.1039/C5TB02123E
Author version available: Download Author version (PDF)
Citation: J. Mater. Chem. B, 2016,4, 32-36
  •   Request permissions

    Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy

    Q. Mu, G. Lin, V. K. Patton, K. Wang, O. W. Press and M. Zhang, J. Mater. Chem. B, 2016, 4, 32
    DOI: 10.1039/C5TB02123E

Search articles by author

Spotlight

Advertisements